It is defined as the inability to achieve pregnancy with regular sexual intercourse for at least 12 months which can potentially benefit from stem cell therapy. Stem cells have shown promise in restoring fertility by improving ovarian function in cases like premature ovarian failure (POF), enhancing oocyte quality, and regenerating endometrial tissue in conditions such as thin endometrium or Asherman’s syndrome. Mesenchymal stem cells (MSCs) may boost hormone production, promote folliculogenesis, and improve implantation rates. Additionally, their immune-modulatory properties could help reduce recurrent pregnancy loss, while their anti-inflammatory effects may contribute to clinical improvement in Polycystic Ovary Syndrome.